Hydrocortisone
Treatment for Addison's Disease
Typical Dosage: 15-25 mg daily, divided into 2-3 doses
Effectiveness
98%
Safety Score
58%
Clinical Trials
18
Participants
50K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
58
DangerousModerateSafe
Treatment Details
Dosage Range
15-25 mg daily, divided into 2-3 doses
Time to Effect
immediate
Treatment Duration
lifetime
Evidence Quality
HIGHConfidence Score
98%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$200
Monitoring:$450
Side Effect Mgmt:$50
Total Annual:$700
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTQALYs Gained
30
Outcome-Based Costs
Cost per Responder
$714.29
Hydrocortisone Outcomes
for Addison's Disease
Efficacy Outcomes
Overall Effectiveness
+98%
Response Rate
+98%
Common Side Effects
Weight gain
+15%
Osteoporosis
+10%
Insomnia
+8%
Fluid retention
+8%
Mood changes
+7%
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
1 active trial recruiting for Hydrocortisone in Addison's Disease
Endoscopic Ultrasound-guided Radiofrequency Ablation in Primary Aldosteronism
NCT05368090RECRUITINGNA
60 participants
INTERVENTIONAL
Bergen, Norway
Started: Jun 3, 2022
Completed Clinical Trials
12 completed trials for Hydrocortisone in Addison's Disease
Glucocorticoid Treatment in Addison's Disease
NCT01063569COMPLETEDPHASE2, PHASE3
33 participants
INTERVENTIONAL
Bergen, Norway +2 more
Started: Feb 1, 2010
Ultradian Subcutaneous Hydrocortisone Infusion in Addison Disease and Congenital Adrenal Hyperplasia
NCT02096510COMPLETEDPHASE1, PHASE2
8 participants
INTERVENTIONAL
Bergen, Norway
Started: Mar 27, 2014
Pharmacokinetics of Hydrocortisone After Subcutaneous Administration in Chronic Adrenal Insufficiency
NCT01450930COMPLETEDPHASE2
12 participants
INTERVENTIONAL
Würzburg, Germany
Started: Nov 1, 2011
Biomarker(s) for Glucocorticoids
NCT02152553COMPLETEDNA
11 participants
INTERVENTIONAL
Gothenburg, Sweden
Started: May 1, 2014
The Hypothalamic-Pituitary-Adrenal (HPA) Axis as an Effector System in Weight Regulation
NCT00688987COMPLETEDNA
24 participants
INTERVENTIONAL
Portland, United States
Started: Aug 1, 2000
Chronocort Versus Plenadren Replacement Therapy in Adults With Adrenal Insufficiency
NCT05222152COMPLETEDPHASE2
58 participants
INTERVENTIONAL
Hamburg, Germany +7 more
Started: Nov 23, 2021
Dual RElease Hydrocortisone Versus conventionAl Glucocorticoid replaceMent Therapy in Hypocortisolism (DREAM)
NCT02277587COMPLETEDPHASE4
89 participants
INTERVENTIONAL
Rome, Italy
Started: Mar 1, 2014
A Study of Markers of Glucocorticoid Effects in Patients With Addisons Disease (DOSCORT)
NCT03210545COMPLETEDPHASE4
30 participants
INTERVENTIONAL
Gothenburg, Sweden
Started: Mar 2, 2021
Test Predicting Adrenal Insufficiency in Volunteers Under Prednisone Treatment
NCT00975078COMPLETEDPHASE4
39 participants
INTERVENTIONAL
Basel, Switzerland
Started: May 1, 2009
Once-daily Oral Modified Release Hydrocortisone in Patients With Adrenal Insufficiency
NCT00915343COMPLETEDPHASE2, PHASE3
64 participants
INTERVENTIONAL
Started: Aug 21, 2007
Effect of Etomidate on Hemodynamics and Adrenocortical Function After Cardiac Surgery
NCT00415701COMPLETEDPHASE4
130 participants
INTERVENTIONAL
Bern, Switzerland
Started: Nov 1, 2006
Cardiovascular Status in Adrenal Insufficiency
NCT03426319COMPLETED
68 participants
OBSERVATIONAL
Würzburg, Germany
Started: Aug 1, 2013